NLRP3 and hepatocellular carcinoma: Also, there is a statistically insignificant decrease in NLRP3 and CASP1 expression levels in late HCC stages when compared with early ones suggesting that the HCC patients with lower NLRP3 and CASP1 expression levels are prone to have more advanced stages (stages III and IV) and poorer cancer cell differentiation (Grade III).